Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

Also called NCT06948292

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Ebima Clifford Okundaye (from the registry)
Registry
  • NCT NCT06948292
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06948292. Non-randomized; double masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-08-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
Acronym
QRX-3 in CKD
Condition
Chronic Kidney Disease Stages 3-5
Condition
Diabetic Kidney Disease
Condition
Hypertensive Kidney Disease
Intervention (Drug)
QRX-3
Lead sponsor
Ebima Clifford Okundaye (class: industry)

Record details

Record id
cardio:ct-nct06948292
Content hash
85f1d52089eeb1fd53a1c7830f2c1cc7fc3cfc5ff546534c30369f4c72e548f8